Lyell Immunopharma (LYEL) Interest Coverage Ratio (2020 - 2026)
Lyell Immunopharma (LYEL) reported Interest Coverage Ratio of 0.75 for Q1 2026, up 6.18% on a YoY basis from 0.71 in Q1 2025, and up 89.91% sequentially from 7.47 in Q4 2025.
Lyell Immunopharma (LYEL) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Interest Coverage Ratio data on file, last reported at 0.75 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 6.18% year-over-year to 0.75; the trailing twelve-month figure through Mar 2026 stood at 4.37 (up 13.56% YoY), and the FY2025 full-year result was 15.76, down 1479.39% from the prior year.
- Interest Coverage Ratio rose to 0.75 in Q1 2026, from 7.47 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.08 in Q4 2022 to a low of 7.47 in Q4 2025.
- A 5-year average of 1.59 and a median of 0.67 in 2022 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio surged 87.25% in 2022 and slumped 1234.66% in 2025, its largest moves.
- Tracing LYEL's Interest Coverage Ratio over 5 years: stood at 0.08 in 2022, then sank by 191.87% to 0.24 in 2023, then sank by 133.61% to 0.56 in 2024, then tumbled by 1234.66% to 7.47 in 2025, then soared by 89.91% to 0.75 in 2026.
- Business Quant data shows LYEL's Interest Coverage Ratio at 0.75 in Q1 2026, 7.47 in Q4 2025, and 0.57 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | -0.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.75 |
| Dec 31, 2025 | -7.47 |
| Sep 30, 2025 | -0.57 |
| Jun 30, 2025 | -0.69 |
| Mar 31, 2025 | -0.80 |
| Dec 31, 2024 | -0.56 |
| Sep 30, 2024 | -0.67 |
| Jun 30, 2024 | -0.66 |
| Mar 31, 2024 | -2.92 |
| Dec 31, 2023 | -0.24 |
| Sep 30, 2023 | -4.84 |
| Jun 30, 2023 | -2.50 |
| Mar 31, 2023 | -2.56 |
| Dec 31, 2022 | -0.08 |
| Sep 30, 2022 | -0.55 |
| Jun 30, 2022 | -0.41 |
| Mar 31, 2022 | -0.67 |
| Dec 31, 2021 | -0.37 |
| Sep 30, 2021 | -4.33 |
| Jun 30, 2021 | -0.56 |